Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
12 nov. 2024 16h01 HE
|
Journey Medical Corporation
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 ...
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
04 nov. 2024 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
25 oct. 2024 08h30 HE
|
Journey Medical Corporation
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy...
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
03 oct. 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
09 sept. 2024 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h15 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12 août 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase...
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024
06 août 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Sol-Gel Technologies Announces Management Realignment
15 juil. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
11 juil. 2024 16h05 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...